Ellen S. Vitetta
About
In The Last Decade
Ellen S. Vitetta
250 papers receiving 10.6k citations
Hit Papers
Peers
Comparison fields: 5 of 134
- Immunology 6.9k
- Molecular Biology 3.7k
- Radiology, Nuclear Medicine and Imaging 3.3k
- Biotechnology 2.1k
- Oncology 1.9k
Countries citing papers authored by Ellen S. Vitetta
This map shows the geographic impact of Ellen S. Vitetta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen S. Vitetta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen S. Vitetta more than expected).
Fields of papers citing papers by Ellen S. Vitetta
This network shows the impact of papers produced by Ellen S. Vitetta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen S. Vitetta. The network helps show where Ellen S. Vitetta may publish in the future.
Co-authorship network of co-authors of Ellen S. Vitetta
This figure shows the co-authorship network connecting the top 25 collaborators of Ellen S. Vitetta. A scholar is included among the top collaborators of Ellen S. Vitetta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen S. Vitetta. Ellen S. Vitetta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 8 | |
| 2 | 55 | |
| 3 | 69 | |
| 4 | 13 | |
| 5 | 4 | |
| 6 | 14 | |
| 7 | 12 | |
| 8 | Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. | 138 |
| 9 | Optimized clinical-scale culture conditions for ex vivoselective depletion of host-reactive donor lymphocytes: astrategy for GVHD prophylaxis in allogeneic peripheral bloodstem cell transplantation | 1 |
| 10 | 168 | |
| 11 | 2 | |
| 12 | 4 | |
| 13 | 116 | |
| 14 | Anti-receptor antibody. I. Isolation and characterization of the immunoglobulin receptor for phosphorylcholine. | 21 |
| 15 | 9 | |
| 16 | 37 | |
| 17 | 22 | |
| 18 | 127 | |
| 19 | 100 | |
| 20 | CELL SURFACE IMMUNOGLOBULIN breakdown → | 335 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.